Trial Profile
An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2014
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 23 Apr 2014 New trial record